General Information of Drug (ID: DMHIS3M)

Drug Name
PRAX-330 Drug Info
Indication
Disease Entry ICD 11 Status REF
Epilepsy 8A60-8A68 Phase 1 [1]
Cross-matching ID
TTD Drug ID
DMHIS3M

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Investigative Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
NBI-921352 DMTTW9V Epileptic encephalopathy 8A62 Phase 2 [2]
XEN901 DMRP9YF Epilepsy 8A60-8A68 Phase 1 [3]
batrachotoxin DMYH9SU Discovery agent N.A. Investigative [4]
veratridine DMUF8JZ Discovery agent N.A. Investigative [4]
4,9-anhydro-tetrodotoxin DMEKI1B Discovery agent N.A. Investigative [5]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Voltage-gated sodium channel alpha Nav1.6 (SCN8A) TT54ERL SCN8A_HUMAN Inhibitor [1]

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 Clinical pipeline report, company report or official report of Neurocrine Biosciences
3 Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
4 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 583).
5 The TTX metabolite 4,9-anhydro-TTX is a highly specific blocker of the Na(v1.6) voltage-dependent sodium channel. Am J Physiol Cell Physiol. 2007 Aug;293(2):C783-9.